ESHRE 2018 - Interview - Prof Klaus Dugi

Yes, I would say in a global world now, for instance in China, with the one-child policy abandoned and demographic changes, there is a growing need for assisted reproductive technology. Globally, about one in six couples have difficulty conceiving. We are committed to helping. Personalized or individualized treatment is important because one-size-fits-all doesn't work due to differences in age, weight, and genetics. The same is true for fertility. We use hormones to stimulate the ovaries, and the response varies with age. We have developed an algorithm based on AMH levels. In phase 3 trials with over 1,300 women and 20,000 cycles, we showed that this individualized dosing algorithm works and is at least as effective. We also looked for an immune response and found it safe. At this Congress, we presented data showing that AMH levels are stable in 95% of women, which reassures fertility doctors that this is a viable approach. We are conducting trials with Google, in Asia, and planning larger trials in the US and Europe. Rekovelle has been launched in 37 countries and feedback is positive. We have a publication in the New England Journal of Medicine. We are collaborating with the Chinese Academy of Science to find new treatments. We work with patient advocacy groups and use the internet to provide information. We are exploring genomics, the microbiome, and big data to improve success rates. We are excited but stay grounded in scientific data. Our goal is to increase success rates and ensure all couples have access to treatment.